-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 32.9% in August
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 32.9% in August
Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 396,100 shares, a drop of 32.9% from the August 15th total of 590,700 shares. Currently, 2.5% of the company's shares are sold short. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 0.4 days.
Hedge Funds Weigh In On Sunshine Biopharma
Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $31,000. Virtu Financial LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $34,000. Bank of Montreal Can purchased a new position in Sunshine Biopharma in the 2nd quarter worth about $40,000. Finally, Empery Asset Management LP purchased a new position in Sunshine Biopharma in the 1st quarter worth about $1,104,000. Hedge funds and other institutional investors own 3.90% of the company's stock.
Get Sunshine Biopharma alerts:Sunshine Biopharma Price Performance
Shares of SBFM opened at $1.04 on Wednesday. The business's 50-day moving average price is $1.14 and its 200 day moving average price is $1.98. Sunshine Biopharma has a 1-year low of $1.01 and a 1-year high of $29.80.
About Sunshine Biopharma
(Get Rating)Sunshine Biopharma, Inc, a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
See Also
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 396,100 shares, a drop of 32.9% from the August 15th total of 590,700 shares. Currently, 2.5% of the company's shares are sold short. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 0.4 days.
阳光生物医药股份有限公司(纳斯达克代码:SBFM-GET Rating)是空头股数8月份大幅下跌的目标。截至8月31日,空头股数共有39.61万股,较8月15日的59.07万股下降了32.9%。目前,该公司2.5%的股票被卖空。根据日均成交量1,100,000股计算,目前天数与回补比率为0.4天。
Hedge Funds Weigh In On Sunshine Biopharma
对冲基金参与阳光生物医药
Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $31,000. Virtu Financial LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $34,000. Bank of Montreal Can purchased a new position in Sunshine Biopharma in the 2nd quarter worth about $40,000. Finally, Empery Asset Management LP purchased a new position in Sunshine Biopharma in the 1st quarter worth about $1,104,000. Hedge funds and other institutional investors own 3.90% of the company's stock.
机构投资者最近买卖了该股的股票。简街集团(Jane Street Group LLC)在第一季度购买了阳光生物医药的一个新头寸,价值约3.1万美元。Virtu Financial LLC在第一季度购买了阳光生物医药的新头寸,价值约3.4万美元。蒙特利尔银行可以在第二季度购买阳光生物医药的一个新头寸,价值约4万美元。最后,Empery Asset Management LP在第一季度购买了阳光生物医药的一个新头寸,价值约1,104,000美元。对冲基金和其他机构投资者持有该公司3.90%的股份。
Sunshine Biopharma Price Performance
阳光生物医药价格表现
Shares of SBFM opened at $1.04 on Wednesday. The business's 50-day moving average price is $1.14 and its 200 day moving average price is $1.98. Sunshine Biopharma has a 1-year low of $1.01 and a 1-year high of $29.80.
周三,SBFM的股价开盘报1.04美元。该业务的50日移动均线价格为1.14美元,200日移动均线价格为1.98美元。阳光生物医药的一年低点为1.01美元,一年高位为29.80美元。
About Sunshine Biopharma
关于阳光生物医药
Sunshine Biopharma, Inc, a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
阳光生物医药公司是一家制药和营养补充剂公司,专注于抗癌药物的研发。该公司正在开发Adva-27A,一种鬼臼毒素的宝石二氟碳糖苷衍生物,用于治疗白血病、淋巴瘤、睾丸、肺癌、脑、前列腺癌、膀胱癌、结肠癌、卵巢、肝癌和其他形式的癌症,以及杀死多药耐药癌细胞,包括胰腺癌、乳腺癌、小细胞肺癌和子宫肉瘤细胞;以及SBFM-PL4,一种抗冠状病毒治疗化合物。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免费获取StockNews.com关于阳光生物医学的研究报告(SBFM)
- 这三份报告将告诉我们许多关于当前经济的情况。
- 下面的五个是不是打得太高了?
- 这就是现在对标准普尔500指数的预期
- 关于甲骨文的FQ1报告,你需要知道的两件事
- 波动市场的三只价值股
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阳光生物报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对阳光生物医药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧